Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $62.69, for a total transaction of $134,532.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Scott Biller also recently made the following trade(s):

  • On Wednesday, October 4th, Scott Biller sold 10,470 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $70.00, for a total transaction of $732,900.00.
  • On Monday, October 2nd, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $67.23, for a total transaction of $144,275.58.
  • On Monday, September 11th, Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.00, for a total transaction of $975,000.00.
  • On Friday, September 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54.

Agios Pharmaceuticals, Inc. (NASDAQ AGIO) traded up $4.48 during midday trading on Friday, hitting $66.49. 354,476 shares of the company were exchanged, compared to its average volume of 410,645.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company’s revenue was up 26.4% on a year-over-year basis. During the same period last year, the firm posted ($1.63) EPS. analysts predict that Agios Pharmaceuticals, Inc. will post -6.89 EPS for the current year.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/agios-pharmaceuticals-inc-agio-insider-scott-biller-sells-2146-shares.html.

A number of equities research analysts have commented on AGIO shares. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank Of Canada started coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective on the stock. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and an average price target of $75.70.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC grew its position in shares of Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after buying an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after buying an additional 617,379 shares during the last quarter. Capital International Investors grew its position in shares of Agios Pharmaceuticals by 11.6% in the 2nd quarter. Capital International Investors now owns 3,129,837 shares of the biopharmaceutical company’s stock valued at $161,030,000 after buying an additional 325,310 shares during the last quarter. BB Biotech AG grew its position in shares of Agios Pharmaceuticals by 1.1% in the 2nd quarter. BB Biotech AG now owns 2,869,528 shares of the biopharmaceutical company’s stock valued at $147,637,000 after buying an additional 30,000 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of Agios Pharmaceuticals by 23.5% in the 2nd quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock valued at $137,648,000 after buying an additional 508,306 shares during the last quarter. 93.46% of the stock is currently owned by hedge funds and other institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.